Obesity Pill Data Signal Competition, Hit Drugmaker Shares
Nov 4, 2024 · Lilly is in advanced clinical trials for its oral drug, orforglipron, which produced an average loss of about 15% of body weight in 36 weeks when given daily at the highest dose to adults with ...
Drugmakers are racing to find the next Wegovy. These obesity …
Oct 15, 2024 · An obesity pill Novo has advanced an oral version of Wegovy and Lilly has pushed its pill oforglipron into phase 3 trials. But there are many rivals staking their competitive future on the idea that people with obesity will prefer a pill over a shot.
Viking Therapeutics soars as early-stage oral obesity drug data
Patients who received the higher dose 100 milligram version of the oral drug, VK2735, showed an 8.2% reduction in body weight on average after 28 days, compared to 1.4% for placebo.
Next-generation drug from Eli Lilly boosts weight loss to 24% ... - CNN
Jun 26, 2023 · An experimental drug from Eli Lilly helped patients with obesity lose an average of 24% of their body weight over 48 weeks on the highest dose in a mid-stage study, the most weight loss seen...
AstraZeneca's Obesity Pills Revealed Positive Result In Phase I Trials
Nov 5, 2024 · Latest News. Stock Market. Originals. The Morning Brief. Premium News. ... revealed positive initial clinical trial results for its obesity drug candidate the oral GLP-1 pill AZD5004 and a ...
New Oral Weight Loss Drugs: Where Are We and What's Next? - Medscape
Jun 5, 2024 · Novo Nordisk's spokesperson told Medscape Medical News that, as announced in March, results from an exploratory endpoint on body weight change in a phase 1 trial showed an average −13.1%...
The Race for the Next Ozempic | WIRED
Jul 24, 2024 · Researchers are now racing to develop new anti-obesity medications that are more effective, more convenient, or produce fewer side effects than the ones currently on the market.
Daily pill from Eli Lilly leads to 15% weight loss in midstage ... - CNN
Jun 23, 2023 · CNN — Eli Lilly’s experimental pill for weight loss helped people lose an average of 15% of their body weight after 36 weeks on the highest dose in a midstage trial, rivaling what’s seen with...
FDA approves Eli Lilly’s Zepbound, a weight loss drug ... - NBC News
Nov 8, 2023 · The Food and Drug Administration on Wednesday approved Zepbound, a new weight loss drug from drugmaker Eli Lilly that was shown in clinical trials to help people lose up to 52 pounds in 16 months.
FDA approves Zepbound, new Wegovy rival : Shots - Health News : NPR
Nov 8, 2023 · An obesity drug called Zepbound won approval for use in adults from the Food and Drug Administration Wednesday, ushering in a new rival to Novo Nordisk's blockbuster Wegovy.